eGenesis is a biotechnology company which offers xenotransplantation technologies to patients with life-threatening conditions. This company was founded by George Church Ph.D and Luhan Yang Ph.D in 2015 and is headquartered in Cambridge, MA. eGenesis uses advanced gene-editing techniques, including CRISPR, to engineer animal organs intended for transplantation into human patients, aiming to provide a sustainable source of organs and tissues.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
09/04/2024 | Series D-1 | $100.04MM | $xx.xx | $332.59MM | Lux Capital, ARCH Venture Partners, Khosla Ventures, Farallon Capital Management, Alta Partners, Fresenius Medical Care Ventures, Leaps by Bayer, DaVita, Eisai Innovation, NATCO Pharmaceuticals, Parkwood Corporation | |
Price per Share
$xx.xx
Shares Outstanding
725,952,593
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Lux Capital, ARCH Venture Partners, Khosla Ventures, Farallon Capital Management, Alta Partners, Fresenius Medical Care Ventures, Leaps by Bayer, DaVita, Eisai Innovation, NATCO Pharmaceuticals, Parkwood Corporation
|
||||||
09/04/2024 | Series D | $90.96MM | $xx.xx | $332.59MM | Lux Capital, ARCH Venture Partners, Khosla Ventures, Farallon Capital Management, Alta Partners, Fresenius Medical Care Ventures, Leaps by Bayer, DaVita, Eisai Innovation, NATCO Pharmaceuticals, Parkwood Corporation | |
Price per Share
$xx.xx
Shares Outstanding
461,979,343
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Lux Capital, ARCH Venture Partners, Khosla Ventures, Farallon Capital Management, Alta Partners, Fresenius Medical Care Ventures, Leaps by Bayer, DaVita, Eisai Innovation, NATCO Pharmaceuticals, Parkwood Corporation
|
||||||
02/03/2021 | Series C-1 | $99.23MM | $xx.xx | $387.57MM | Farallon Capital Management, Polaris Partners, HBM Healthcare Investments, Invus, Samsara BioCapital, LifeSci Venture Partners, Irving Investors, Catalio Capital Management, SymBiosis, Altium Capital, Monashee Investment Management, Osage University Partners, Leaps by Bayer, Fresenius Medical Care Ventures, ARCH Venture Partners, Wellington Partners, Khosla Ventures, Alta Partners | |
Price per Share
$xx.xx
Shares Outstanding
50,860,191
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Farallon Capital Management, Polaris Partners, HBM Healthcare Investments, Invus, Samsara BioCapital, LifeSci Venture Partners, Irving Investors, Catalio Capital Management, SymBiosis, Altium Capital, Monashee Investment Management, Osage University Partners, Leaps by Bayer, Fresenius Medical Care Ventures, ARCH Venture Partners, Wellington Partners, Khosla Ventures, Alta Partners
|
||||||
11/07/2019 | Series B-1 | $99.48MM | $xx.xx | $174.68MM | Fresenius Medical Care Ventures, Leaps by Bayer, Wellington Partners, ARCH Venture Partners, Biomatics Capital, Alta Partners, Khosla Ventures | |
Price per Share
$xx.xx
Shares Outstanding
55,111,122
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Fresenius Medical Care Ventures, Leaps by Bayer, Wellington Partners, ARCH Venture Partners, Biomatics Capital, Alta Partners, Khosla Ventures
|
||||||
03/16/2017 | Series A-1 | $39.15MM | $xx.xx | $56.52MM | Biomatics Capital, ARCH Venture Partners, Khosla Ventures, Alta Partners, Alexandria Venture Investments, Heritage Provider Network, Berggruen Holdings North America, Uprising, Fan Ventures | |
Price per Share
$xx.xx
Shares Outstanding
27,375,893
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Biomatics Capital, ARCH Venture Partners, Khosla Ventures, Alta Partners, Alexandria Venture Investments, Heritage Provider Network, Berggruen Holdings North America, Uprising, Fan Ventures
|